 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...7980818283848586878889...100101» |
- |||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Trial completion date, Trial primary completion date, Combination therapy, Metastases: VICTORIANE: A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease (clinicaltrials.gov) - Mar 9, 2018
P3, N=340, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2018 --> Feb 2019
- | New P3 trial: STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) - Mar 8, 2018
P3, N=50, Not yet recruiting, Sponsor: Gynaecologisch Oncologisch Centrum Zuid
- || Kisqali (ribociclib) / Novartis
Trial completion date, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Mar 7, 2018
P2, N=76, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2018 --> Feb 2019 Trial completion date: Aug 2022 --> Aug 2023
- | letrozole / Generic mfg.
Trial primary completion date: SOLE: Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (clinicaltrials.gov) - Mar 6, 2018
P3, N=4884, Active, not recruiting, Sponsor: International Breast Cancer Study Group
Trial completion date: Aug 2022 --> Aug 2023 Trial primary completion date: Dec 2021 --> Apr 2019
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 6, 2018
P2, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2021 --> Apr 2019 Trial completion date: Nov 2017 --> Nov 2018 | Trial primary completion date: Nov 2017 --> Nov 2018
- | letrozole / Generic mfg.
New trial: Intrauterine Insemination With Letrozole Versus in Natural Cycle (clinicaltrials.gov) - Mar 5, 2018
P=N/A, N=100, Not yet recruiting, Sponsor: Peking University Third Hospital
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment closed: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Mar 5, 2018
P3, N=10000, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2017 --> Nov 2018 | Trial primary completion date: Nov 2017 --> Nov 2018 Recruiting --> Active, not recruiting
- | Biomarker, Trial completion: MIRHO: Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (clinicaltrials.gov) - Mar 5, 2018
P4, N=39, Completed, Sponsor: Institut Claudius Regaud
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Mar 3, 2018
P1, N=88, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Sep 2018 --> Oct 2018
- || Piqray (alpelisib) / Novartis, buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date: Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women (clinicaltrials.gov) - Mar 3, 2018
P2, N=340, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2018 --> Oct 2018 Trial primary completion date: Jul 2017 --> Jul 2017
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Mar 3, 2018
P1, N=253, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2017 --> Jul 2017 Trial primary completion date: Apr 2019 --> May 2019
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial initiation date, PARP Biomarker: IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (clinicaltrials.gov) - Mar 3, 2018
P1, N=143, Not yet recruiting, Sponsor: Haukeland University Hospital
Trial primary completion date: Apr 2019 --> May 2019 Initiation date: Feb 2018 --> Apr 2018
- || PF-06804103 / Pfizer
Trial completion date, Trial primary completion date: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Mar 3, 2018
P1, N=95, Recruiting, Sponsor: Pfizer
Initiation date: Feb 2018 --> Apr 2018 Trial completion date: Aug 2020 --> Nov 2020 | Trial primary completion date: Aug 2020 --> Nov 2020
- || Trial completion date, Trial initiation date, Trial primary completion date, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=320, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Aug 2020 --> Nov 2020 | Trial primary completion date: Aug 2020 --> Nov 2020 Trial completion date: Dec 2019 --> Dec 2019 | Initiation date: Mar 2016 --> Mar 2016 | Trial primary completion date: Dec 2019 --> Dec 2019
- || Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer (clinicaltrials.gov) - Mar 2, 2018
P2, N=75, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial completion date: Dec 2019 --> Dec 2019 | Initiation date: Mar 2016 --> Mar 2016 | Trial primary completion date: Dec 2019 --> Dec 2019 Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Aug 2018 --> Jan 2020
- | tamoxifen / Generic mfg.
Biomarker, Trial completion, Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy: PHACS: Pharmacology of Adjuvant Hormonotherapy in Breast Cancer (clinicaltrials.gov) - Mar 2, 2018
P4, N=2000, Completed, Sponsor: Institut Claudius Regaud
Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Aug 2018 --> Jan 2020 Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Dec 2017 | Trial completion date: Jun 2019 --> Dec 2017 | Initiation date: May 2010 --> Jun 2010
- |||| Enrollment open, Trial initiation date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 2, 2018
P1/2, N=260, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Dec 2017 | Trial completion date: Jun 2019 --> Dec 2017 | Initiation date: May 2010 --> Jun 2010 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Mar 2018
- | Review, Journal: Recent advances of highly selective CDK4/6 inhibitors in breast cancer. (Pubmed Central) - Mar 1, 2018
Besides, the favorable effects of abemaciclib on prolonging survival of breast cancer patients have also been observed in clinical trials both for single-agent and combination strategy. In this review, we outline the preclinical and clinical advancement of these three orally bioavailable and highly selective CDK4/6 inhibitors in breast cancer.
- | Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 1, 2018
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
In this review, we outline the preclinical and clinical advancement of these three orally bioavailable and highly selective CDK4/6 inhibitors in breast cancer. Trial primary completion date: Jan 2018 --> Dec 2014 | Trial completion date: Apr 2018 --> Sep 2018
- || Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 23, 2018
P4, N=73, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2018 --> Dec 2014 | Trial completion date: Apr 2018 --> Sep 2018 Trial primary completion date: Apr 2017 --> Nov 2012
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: PALLET: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (clinicaltrials.gov) - Feb 23, 2018
P2, N=306, Recruiting, Sponsor: NSABP Foundation Inc
Trial primary completion date: Apr 2017 --> Nov 2012 Trial primary completion date: Jul 2017 --> Apr 2018 | Trial completion date: Oct 2017 --> May 2018
- letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 22, 2018
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Apr 2018 | Trial completion date: Oct 2017 --> May 2018 Trial primary completion date: Apr 2018 --> Apr 2020 | Trial completion date: Apr 2018 --> Apr 2021
- |||||||||| progesterone / Generic mfg., letrozole / Generic mfg.
New P2/3 trial: Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole (clinicaltrials.gov) - Feb 22, 2018
P2/3, N=52, Completed, Sponsor: Eastern Virginia Medical School
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
New P3 trial, Tumor mutational burden, Metastases: BioItaLEE: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (clinicaltrials.gov) - Feb 20, 2018
P3, N=350, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: HERAKLES: Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women (clinicaltrials.gov) - Feb 15, 2018
P2, N=132, Recruiting, Sponsor: Gangnam Severance Hospital
Trial primary completion date: Apr 2018 --> Apr 2020 | Trial completion date: Apr 2018 --> Apr 2021 Trial primary completion date: Oct 2017 --> Mar 2019 | Trial completion date: Sep 2018 --> Jun 2019
- Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Metastases: Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone (clinicaltrials.gov) - Feb 13, 2018
P2, N=44, Active, not recruiting, Sponsor: Translational Research in Oncology
Trial primary completion date: Oct 2017 --> Mar 2019 | Trial completion date: Sep 2018 --> Jun 2019 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Brovale: Fertility Preservation in Breast Cancer Patients (clinicaltrials.gov) - Feb 12, 2018
P4, N=54, Recruiting, Sponsor: Erasme University Hospital
Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Mar 2017 --> Mar 2018 | Trial completion date: Dec 2021 --> Dec 2022
- | Soltamox (tamoxifen citrate) / Jazz
Enrollment open, Trial initiation date, IO biomarker: PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov) - Feb 12, 2018
P2, N=39, Recruiting, Sponsor: Medical College of Wisconsin
Trial primary completion date: Mar 2017 --> Mar 2018 | Trial completion date: Dec 2021 --> Dec 2022 Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Feb 2017
- dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment change, Trial termination, Combination therapy, Metastases: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer (clinicaltrials.gov) - Feb 9, 2018
P1/2, N=12, Terminated, Sponsor: Georgetown University
Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Feb 2017 N=36 --> 12 | Active, not recruiting --> Terminated; Decision by company to cease development of dovitinib
- |||| letrozole / Generic mfg.
Trial completion, Trial primary completion date: VITAL: Vitamin D3 for Aromatase Inhibitor Induced Arthralgias (clinicaltrials.gov) - Feb 9, 2018
P2, N=160, Completed, Sponsor: Qamar Khan
N=36 --> 12 | Active, not recruiting --> Terminated; Decision by company to cease development of dovitinib Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jan 2011
- | paclitaxel / Generic mfg.
Trial initiation date: ARETTA: Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Feb 7, 2018
P2, N=60, Not yet recruiting, Sponsor: University of Chicago
Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jan 2011 Initiation date: Nov 2017 --> Nov 2018
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Feb 6, 2018
P=N/A, N=150, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Nov 2017 --> Nov 2018 Trial primary completion date: Sep 2017 --> Sep 2018
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: NEOLBC: Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. (clinicaltrials.gov) - Feb 6, 2018
P2, N=100, Not yet recruiting, Sponsor: Borstkanker Onderzoek Groep
Trial primary completion date: Sep 2017 --> Sep 2018 Initiation date: Nov 2017 --> Feb 2018 | Trial primary completion date: Apr 2020 --> Jul 2020 | Trial completion date: Nov 2024 --> Feb 2025
- | letrozole / Generic mfg.
Trial completion, Trial completion date: Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment (clinicaltrials.gov) - Feb 6, 2018
P2/3, N=35, Completed, Sponsor: Helsinki University Central Hospital
Initiation date: Nov 2017 --> Feb 2018 | Trial primary completion date: Apr 2020 --> Jul 2020 | Trial completion date: Nov 2024 --> Feb 2025 Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Feb 2018
- ||||| New P1/2 trial: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Feb 5, 2018
P1/2, N=260, Not yet recruiting, Sponsor: Hoffmann-La Roche
- everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Feb 5, 2018
P2, N=48, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Feb 2018 Trial primary completion date: Nov 2017 --> Jan 2019
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, HEOR, Patient reported outcomes, Metastases: PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) - Feb 5, 2018
P4, N=960, Recruiting, Sponsor: Palleos Healthcare GmbH
Trial primary completion date: Nov 2017 --> Jan 2019 Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Jun 2017
- | Piqray (alpelisib) / Novartis
P1 data, Journal: A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer. (Pubmed Central) - Feb 4, 2018
Clinical activity was observed independently of PIK3CA mutation status although clinical benefit was seen in a higher proportion of patients with PIK3CA mutated tumors. Phase II and III trials of alpelisib and endocrine therapy in patients with ER+ breast cancer are ongoing.
- |||| Bizengri (zenocutuzumab-zbco) / Merus, Partner Therap
Enrollment open: MCLA-128-CL02: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (clinicaltrials.gov) - Jan 30, 2018
P2, N=120, Recruiting, Sponsor: Merus N.V.
Phase II and III trials of alpelisib and endocrine therapy in patients with ER+ breast cancer are ongoing. Not yet recruiting --> Recruiting
- | Soltamox (tamoxifen citrate) / Jazz
Trial primary completion date: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (clinicaltrials.gov) - Jan 29, 2018
P3, N=11248, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> May 2018
- | Trial primary completion date: Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients (clinicaltrials.gov) - Jan 19, 2018
P3, N=107, Recruiting, Sponsor: Dharmais National Cancer Center Hospital
Trial primary completion date: Dec 2017 --> May 2018 Trial primary completion date: Mar 2017 --> Mar 2018
- Ibrance (palbociclib) / Pfizer
Phase classification, Combination therapy, Metastases: Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=0, No Longer Available, Sponsor: Pfizer
Trial primary completion date: Mar 2017 --> Mar 2018 Phase classification: P3 --> P=N/A
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: RIBECCA: Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 17, 2018
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P3 --> P=N/A Initiation date: Oct 2016 --> Jun 2016
- | letrozole / Generic mfg.
New trial: Different Methods of Termination of Second Trimester Abortion (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=150, Not yet recruiting, Sponsor: Cairo University
- ||| letrozole / Generic mfg.
New P1 trial: Evaluation of IM Letrozole ISM (clinicaltrials.gov) - Jan 16, 2018
P1, N=120, Recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: PARSIFAL: Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jan 16, 2018
P2, N=486, Active, not recruiting, Sponsor: MedSIR
Initiation date: Oct 2016 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Jan 2019
- | letrozole / Generic mfg.
New P2 trial: Neoadjuvant Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Jan 12, 2018
P2, N=46, Completed, Sponsor: Guangdong General Hospital
- | Trial primary completion date: ACCN: Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer (clinicaltrials.gov) - Jan 9, 2018
P3, N=120, Recruiting, Sponsor: Zhejiang Cancer Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Jan 2019 Trial primary completion date: Dec 2017 --> Jul 2018
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jan 3, 2018
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Jul 2018 Trial primary completion date: Feb 2018 --> Aug 2019
- | letrozole / Generic mfg.
Enrollment change, BRCA Biomarker: LIBER: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation (clinicaltrials.gov) - Dec 30, 2017
P3, N=386, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Feb 2018 --> Aug 2019 N=724 --> 386